

F. No.50014/03/2020-CDN
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

Shastri Bhawan, New Delhi
Dated: 30 November, 2021

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of October, 2021-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of October, 2021 for information.



(Shamim Uddin Ansari)

Under Secretary to the Govt. of India

To,

1. All members of Council of Ministers.
2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
3. The Principal information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

1. Secretaries to the Govt. of India, All Ministries/Department.
2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
5. PS to Prime Minister of India, South Block, New Delhi-110004.
6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
7. Sr.PPS to Secretary (Pharma).
8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
Monthly Summary for the Month of October, 2021

Important events for the Month of **October, 2021** are as follows:

1. IMPORTANT POLICY DECISIONS:

NIL

2. MAJOR ACHIEVEMENTS:

- (i) **Investors Summit:** The Department of Pharmaceuticals in collaboration with Invest India organized an Investors Summit on Opportunities and Partnerships in Pharmaceuticals and Medical Devices virtually on 27th of October 2021 from 10:00 AM- 4:30 PM to uncover several exciting opportunities for growth and investment across the Pharmaceuticals and Medical Devices ecosystem. The Summit was graced by Dr. Mansukh Mandaviya, Hon'ble Minister for Chemicals and Fertilizers and Health & Family Welfare as the Guest of Honour. The Investors Summit conducted five detailed technical sessions with a laser-eyed focus to explore opportunities for domestic R&D driven manufacturing in bio-pharmaceuticals, becoming the land of opportunities for medical devices with expansion of diagnostics and medical equipment, financing the growing startup ecosystem, and provide comprehensive facilitation and support to PLI applicants.
- (ii) **Meeting with the representatives of in-principle approved States under the scheme "Promotion of Medical Devices Parks":** Under the scheme "Promotion of Medical Devices Parks", four states i.e. Himachal Pradesh, Tamil Nadu, Madhya Pradesh & Uttar Pradesh were given in-principle approval vide letters dated 24.09.2021. To discuss the design of the upcoming Medical Devices Parks, a meeting was held under the chairmanship of Secretary, Department of Pharmaceuticals on 20.10.2021. The States were advised to work together in collaboration so as to complement each other so that all target segments can be covered efficiently. Each State should take up the focus segment of the medical devices which will be manufactured in the park on the basis of its respective strength. States were also advised to visit 2-3 medical device companies or medical devices clusters and to come up with 3-4 possible investors and finalization of their technical partner for the project.
- (iii) **Drugs Coordination Committee:** One meeting of the Drugs Coordination Committee was held on 28.10.2021 wherein procurement orders placed by States/UTs for COVID-19 drugs' buffer stock; adequacy of raw material supply w.r.t. manufacture of drugs used in COVID-19 treatment; Update on monoclonal antibodies licensed for import / manufacture / marketing; export of remdesivir and amphotericin B; manufacturing and availability of IVIG were reviewed.
- (iv) **Export of Remdesivir and Amphotericin-B:** On 01.06.2021 and 14.06.2021, export policy of remdesivir injection / API and Amphotericin-B injections, respectively, was amended from 'Prohibited' to 'Restricted'. Subsequently, DGFT has been referring applications for export in this regard to DoP and DoHFW for recommendations. During **October 2021**, 34,02,415 vials of Remdesivir and 6,11,567 units of Amphotericin B were recommended for export to DGFT.
- (v) **International Cooperation:** This Department participated in the 9th Session of India-Cyprus Joint Committee on Economic Scientific, Technical and Industrial Cooperation (JCEC) held on 21.10.2021 and 1st Joint Working Group (JWG) under

the MoU between India and Italy on cooperation in the field of Health and Medical Sciences wherein areas of collaboration identified included investments in Pharma and medical device sector in India; partnerships between National Institutes of Pharmaceutical Education and Research (NIPERs) and foreign counterpart towards nurturing and promoting quality and excellence in pharmaceutical education and research; Speedy WHO PQ approvals for drugs / vaccines manufactured in India and industry to industry collaboration to promote resilient and diversified supply chains for the world.

- (vi) **Opening of Price Monitoring and Resource Unit (PMRU) - 20th PMRU** was established in UT of Puducherry during the month by **National Pharmaceutical Pricing Authority (NPPA)**
- (vii) **National Webinar organized on 29th October 2021:** As part of activities to commemorate the occasion of 75th anniversary of India's independence during the yearlong 'Azadi Ka Amrit Mahotsav', the NPPA organized a webinar on "Affordability and Innovation: Ensuring Quality Drugs for All" on 29th October, 2021 through video conferencing under chairmanship of Prof. K. Vijay Raghavan, Principal Scientific Adviser to the Government of India. The Webinar was participated by around 350 Participants from industry, academia, Central and State governments, Price Monitoring Resource Units (PMRUs), civil society and patient advocacy groups from all over the country.

Inaugural issue of the bi-monthly newsletter of NPPA was launched during the webinar.
- (viii) **Monitoring of COVID drugs for Buffer Stock:** MoHFW has issued the guidelines for building up the Buffer Stock of Covid medicines with an emphasis on initiatives by the States on procurement for the same. COVID Drug Management cell met on a weekly basis to coordinate and monitor the production, supply and availability of drugs required for COVID management. Special attention was given to domestic manufacture of Mono Clonal Antibodies. NPPA has been assigned the task of coordinating with States/UTs and the manufacturers if any facilitation is required to monitor the supplies once the purchase orders are placed.
NPPA, through 18 PMRU and CDSCO conducted weekly market surveys during October 2021 for COVID Management drugs as well as five medical devices.
- (ix) A meeting was convened with Dr. R. S. Sharma, CEO, National Health Authority (NHA) to discuss the subject of "Tracking of availability of stocks of drugs" on 18th October, 2021. During the meeting, the need for having an IT enabled system to track the availability of stocks of COVID management drugs in the supply chain down to retailer was discussed.
- (x) A week long event with a series of webinars and exhibitions on various aspects of Pharmaceutical developments and challenges was organized by the NIPERs collectively as part of the activities for celebrating Azadi ka Amrut mahotsav.
- (xi) **Special Drive for weeding out of old records:** During the period of the special campaign for disposal of pending matters conducted from 2nd to 31st of October 2021, as many as 8020 physical files have been reviewed, of which 4900 files have been weeded out, apart from conducting 12 cleanliness drives at three locations of the Department.

2. The details of grievances during the **October, 2021** are as under:

No. of grievances at the start of the month	No. of grievances received during the month	No. of grievances disposed	No. of grievances pending at end of the month
48	137	136	49

4. FDI proposals:-

(a) Pending at beginning of the month	:-	16
(b) Received during the month	:-	1
(c) Disposed of during the month	:-	2
(d) Pending at end of the month	:-	15
